Rozlytrek from Roche gets EC approval to treat solid tumours and NSCLC EP News Bureau Aug 3, 2020 The approval is based on results from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I…
Roche’s personalised cancer treatment wins FDA approval Reuters Aug 16, 2019 The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling
